About Philogen
Philogen is a company based in Sovicille (Italy) founded in 1996 by Dario Neri, Giovanni Neri, and Duccio Neri. It operates as a HealthTech, and Licensing Model. Philogen has raised $69.7 million across 3 funding rounds from investors including European Union and The Equity Club. The company has 183 employees as of December 31, 2024. Philogen offers products and services including Nidlegy™, Fibromun, and OncoFAP Radio Conjugates. Philogen operates in a competitive market with competitors including Aclaris Therapeutics, MorphoSys, Escient Pharmaceuticals, Genmab and Nimbus Therapeutics, among others.
- Headquarter Sovicille, Italy
- Employees 183 as on 31 Dec, 2024
- Founders Dario Neri, Giovanni Neri, Duccio Neri
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Philogen Spa
-
Annual Revenue
$76.88 M (USD)219.91as on Dec 31, 2024
-
Net Profit
$47.05 M (USD)0as on Dec 31, 2024
-
EBITDA
$39.44 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$69.7 M (USD)
in 3 rounds
-
Latest Funding Round
$69.7 M (USD), Private Equity Round
May 13, 2019
-
Investors
European Union
& 1 more
-
Employee Count
183
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Philogen
Philogen is a publicly listed company on the MIL with ticker symbol PHIL in Italy, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Philogen
Philogen offers a comprehensive portfolio of products and services, including Nidlegy™, Fibromun, and OncoFAP Radio Conjugates. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A treatment for melanoma is developed by Philogen.
A targeted therapy is offered for cancer treatment.
Imaging and therapy solutions are provided for cancer.
Funding Insights of Philogen
Philogen has successfully raised a total of $69.7M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round round of $69.7 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Private Equity Round — $69.7M
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2019 | Amount | Private Equity Round - Philogen | Valuation | The Equity Club |
|
| Jan, 2017 | Amount | Grant - Philogen | Valuation |
investors |
|
| Nov, 2012 | Amount | Grant - Philogen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Philogen
Philogen has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and The Equity Club. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment initiatives for companies are facilitated by The Equity Club.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Philogen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Philogen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Philogen Comparisons
Competitors of Philogen
Philogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, MorphoSys, Escient Pharmaceuticals, Genmab and Nimbus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Antibody therapeutics for cancer and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Philogen
Frequently Asked Questions about Philogen
When was Philogen founded?
Philogen was founded in 1996 and raised its 1st funding round 16 years after it was founded.
Where is Philogen located?
Philogen is headquartered in Sovicille, Italy. It is registered at Sovicille, Tuscany, Italy.
Who is the current CEO of Philogen?
Dario Neri is the current CEO of Philogen. They have also founded this company.
Is Philogen a funded company?
Philogen is a funded company, having raised a total of $69.7M across 3 funding rounds to date.
How many employees does Philogen have?
As of Dec 31, 2024, the latest employee count at Philogen is 183.
What is the annual revenue of Philogen?
Annual revenue of Philogen is $76.88M as on Dec 31, 2024.
What does Philogen do?
Philogen, a Swiss-Italian biotechnology company, is focused on innovating treatments for cancer and other serious conditions. The company is involved in the development of targeted therapies and imaging solutions within the healthcare sector. Products such as Nidlegy, Fibromun, and OncoFAP Radio Conjugates are developed to address specific cancer treatment needs. Research and development efforts are supported by enabling technologies and strategic partnerships. The company is listed on the Italian Stock Exchange and operates with a mission to advance therapeutic solutions.
Who are the top competitors of Philogen?
Philogen's top competitors include Escient Pharmaceuticals, Forty Seven and Nimbus Therapeutics.
What products or services does Philogen offer?
Philogen offers Nidlegy™, Fibromun, and OncoFAP Radio Conjugates.
Is Philogen publicly traded?
Yes, Philogen is publicly traded on MIL under the ticker symbol PHIL.
Who are Philogen's investors?
Philogen has 2 investors. Key investors include European Union, and The Equity Club.
What is Philogen's ticker symbol?
The ticker symbol of Philogen is PHIL on MIL.